Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADvantage: Topical DS107 in Atopic Dermatitis
NCT02925793Phase 2Completed
- Sponsor
- DS Biopharma
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of DS107E in atopic dermatitis (AD) (3 arms), sponsored by DS Biopharma. Primary endpoints: Numeric Rating Scale for Pruritus at 8 weeks and Eczema Area and Severity Index at 8 weeks. Started Dec 2016; status: completed.
02
Drugs
DS107E
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02925793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925793.